Company: STAA
Filing Date: 2025-02-21
Form Type: 10-K
Source: 0000950170-25-024813
Chunk: 132

Company: STAAR SURGICAL CO
Filing Date: 2025-02-21
Form: 10-K
Item: Item 1B
Chunk 132
---
 under the Equity Plan generally vest based on service, performance, or a combination of both. On June 15, 2023, the Company’s stockholders approved a proposal to increase the number of shares that may be issued pursuant to stock-based awards granted under the Equity Plan, which increased the share pool by 2,170,000 shares. On June 19, 2024, the Company’s stockholders approved a proposal to increase the number of shares that may be issued pursuant to stock-based awards granted under the Equity Plan, which increased the share pool by 2,600,000 shares. As a result of such increases, a total of 22,805,000 shares may be issued pursuant to stock-based awards granted under the Equity Plan. As of December 27, 2024, there were 3,438,028 shares available for grants of stock-based awards under the Equity Plan.Stock-Based CompensationThe following table represents the fair value of stock-based compensation granted during the year ended 2024 (in thousands): 

        Fair Value

        Stock options
         
        $
        13,522

        RSUs

        17,496

        PSUs

        14,665

        Restricted stock

        703

        Total stock-based compensation expense
         
        $
        46,386

       The Company recorded stock-based compensation expense by award as follows (in thousands):  

        Years Ended

        2024

        2023

        2022

        Employee stock options
         
        $
        13,824

        $
        12,842

        $
        10,403

        Restricted stock

        512

        548

        686

        RSUs

        11,739

        7,987

        4,512

        PSUs

        568

        1,270

        3,525

        Nonemployee stock options

        567

        869

        1,245

        Total stock-based compensation expense
         
        $
        27,210

        $
        23,516

        $
        20,371

      The Company recorded stock-based compensation expense in the following categories (in thousands): 

        Years Ended

        2024

        2023

        2022

        Cost of sales
         
        $
        1,192

        $
        716